CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Victor Perlroth

Chairman and Chief Executive Officer, Kodiak Sciences

Search every verified Victor Perlroth interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Victor Perlroth, chairman and CEO of Kodiak Sciences, discussed topline results from the company’s DAYBREAK pivotal Phase 3 study of Zenkuda and KSI-501 during a September 28, 2026 conference call. He described the results as a "definitive milestone" in the field of retina and stated that the company plans to file a Biologics License Application (BLA) for Zenkuda in wet age-related macular degeneration this year, with additional filings planned for diabetic retinopathy and retinal vein occlusion. Perlroth also expressed enthusiasm for advancing KSI-501 in diabetic macular edema and KSI-101 for macular edema secondary to inflammation, noting the potential for the company to transition from a pre-commercial to a commercial stage. Perlroth explained that the DAYBREAK trial was designed to approximate real-world clinical practice, where physicians treat patients based on the presence of intraretinal or subretinal fluid detected on OCT imaging. He highlighted the strength of the Zenkuda data and the safety profile observed in the study, while also noting excitement about the potential of the company’s superiority study design for KSI-501 in DME.

Recent appearances

  • Kodiak Sciences Topline Results from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501

    September 29, 2026 · 📺 i101

    Kodiak Sciences Topline Results from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 | Sep 28, 2026. Twitter - https://x.com/i101yt If you find our work useful, please support us by purchasing a Super Thanks— it truly helps us a lot. #earningscall #StockMarketNews #conferenceCall Earnings Call | Earnings Conference Call | Earnings concall | concall | quarterly results | Stock News | Full Year results | Fiscal Year results | investment news | stock latest news | Annual Meeting of Shareholders | Annual Meeting of Unitholders | Special and Annual Meeting of Shareholders | AGM | Annual…

    Watch on YouTube ↗

  • A view on Antibody Biopolymer Conjugates for Ophthalmology

    October 20, 2021 · 📺 Lonza

    Bridging Business and Biotechnology: Kodiak Sciences Is Increasing Treatment Efficacy for Retinal Diseases Victor Perlroth, MD, the Chairman and CEO of Kodiak Sciences, discusses how the company’s ABC platform medicines are designed to treat the leading causes of blindness. Age-related macular degeneration (AMD) is one of the leading causes of blindness in adults worldwide. This disease deteriorates the macula, a miraculous little spot on your retina that allows for precise vision in good light. Although several treatments exist for macular deterioration, they require frequent trips to the…

    Watch on YouTube ↗

  • Kodiak Sciences Inc KOD CEO Victor Perlroth on Q1 2020 Results

    May 13, 2020 · 📺 Daily Earnings Calls

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →